Home > In process > Shift in motor-state equilibrium explains gait therapy effects of apomorphine in experimental Parkinsonism. > print

001     285741
005     20260320151938.0
024 7 _ |a 10.1016/j.expneurol.2026.115704
|2 doi
024 7 _ |a pmid:41765318
|2 pmid
024 7 _ |a 0014-4886
|2 ISSN
024 7 _ |a 1090-2430
|2 ISSN
037 _ _ |a DZNE-2026-00298
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kabaoglu, Burce
|b 0
245 _ _ |a Shift in motor-state equilibrium explains gait therapy effects of apomorphine in experimental Parkinsonism.
260 _ _ |a Amsterdam [u.a.]
|c 2026
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1774016268_12445
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Gait impairments remain a major therapeutic challenge in Parkinson's disease (PD). Apomorphine is gaining renewed clinical attention with the expanding use of pump infusion systems. Yet the specific role of apomorphine on the neural regulation of gait has remained poorly characterized, limiting its targeted use for symptom-specific therapy in PD. Here, we examined the neurobehavioral effects of apomorphine on runway locomotion in the unilateral 6-hydroxydopamine (6-OHDA) rat model. Therapeutic drug doses significantly increased total walking distance, related to reduced akinesia and prolonged gait episodes. Conversely, 3D kinematic analysis revealed reduced limb velocities under medication. At the neural level, therapy doses selectively enhanced cortical high-gamma rhythms without substantially altering beta or low-gamma activity. Instead, beta and low-gamma oscillations were consistently suppressed during motor activity in both medication ON and OFF conditions. Neurobehavioral correlations showed that transitions into gait were facilitated by reductions in beta and low-gamma activity, whereas transitions to akinesia were primarily suppressed when high-gamma activity was elevated. Our findings highlight that cortical oscillations can serve as state specific biomarkers for gait impairments in PD. We further propose that the complex therapy effects of apomorphine are best explained by a shift in motor-state equilibrium that is defined by the transitions of akinesia, stationary movements and gait. Together, these insights establish a mechanistic framework to guide the development of targeted gait therapies in PD.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Gait therapy
|2 Other
650 _ 7 |a Motor control
|2 Other
650 _ 7 |a Neural oscillations
|2 Other
650 _ 7 |a Parkinson's disease
|2 Other
700 1 _ |a Garulli, Elisa L
|b 1
700 1 _ |a De Sa, Rafael
|b 2
700 1 _ |a Vogt, Arend
|b 3
700 1 _ |a Behrsing, Ruben
|b 4
700 1 _ |a Skrobot, Matej
|b 5
700 1 _ |a Paulat, Raik
|b 6
700 1 _ |a Pollak, Patrick
|b 7
700 1 _ |a Guldin, Lynn S
|b 8
700 1 _ |a Gerster, Moritz
|b 9
700 1 _ |a Neumann, Wolf-Julian
|b 10
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 11
|u dzne
700 1 _ |a Harms, Christoph
|b 12
700 1 _ |a Wenger, Nikolaus
|b 13
773 _ _ |a 10.1016/j.expneurol.2026.115704
|g Vol. 401, p. 115704 -
|0 PERI:(DE-600)1466932-8
|p 115704
|t Experimental neurology
|v 401
|y 2026
|x 0014-4886
856 4 _ |u https://pub.dzne.de/record/285741/files/DZNE-2026-00298.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285741/files/DZNE-2026-00298.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-11-10
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EXP NEUROL : 2022
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-10
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EXP NEUROL : 2022
|d 2025-11-10
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21